Field trials have resulted in significant improvement while leaving minimal footprint
TEL AVIV, Israel–(BUSINESS WIRE)– ICL (NYSE: ICL) (TASE: ICL), a leading global speciality minerals company, and ag-biotech company PlantArcBio, Ltd.(TASE: PLNT), today announced the development of a novel biostimulant technology platform, which will improve crop yields while having a minimal impact on the environment. The platform successfully uses RNAi technology to maximize a plant’s natural yield increase mechanisms, without any genetic modification, and was the result of a multi-year research collaboration between the two companies.
In early-stage canola field trials, the platform has significantly increased seed weight per hectare for canola crops, and ICL and PlantArcBio are planning larger-scale field trials in 2022. These will include testing the new technology platform using both commercial sprayers and standard farming practices. Greenhouse trials for soybeans and rice are already in progress, with early results showing good potential.
“The use of novel biostimulants based on RNAi technology helps promote sustainability, by reducing the use of chemicals in agriculture,” explained Hadar Sutovsky, vice president of External Innovation and general manager of ICL Planet. “This aligns perfectly with ICL’s long-term goal of creating impact and sustainable growth in the agriculture end-market, alongside ensuring food security.” The global biostimulants market was estimated to be $3.2 billion in 2021 and is projected to grow at a CAGR of 12.1 percent to reach $5.6 billion by 2026, according to ReportLinker.com.
“ICL and PlantArcBio have filed for a joint patent on the application for multiple crops,” said Sutovsky. “The application does its work, then rapidly disappears from both the plants and the environment, lasting no more than a few days, as it is highly biodegradable and also leaves no residual footprint.”
“The positive canola field trial results constitute another milestone in strengthening PlantArcBio’s capabilities in the development of RNAi-based products,” said Dror Shalitin, PhD, founder and CEO of PlantArcBio. “ICL, a market leader in crop nutrition products, is a great strategic partner for us to commercialize this sustainable technology worldwide.”
ICL Group is a leading global speciality minerals company, which also benefits from commodity upside. The company creates impactful solutions for humanity’s sustainability challenges in the global food, agriculture, and industrial markets. ICL leverages its unique bromine, potash, and phosphate resources, its passionate team of talented employees, and its strong focus on R&D and technological innovation, to drive growth across its end markets. ICL shares are dually listed on the New York Stock Exchange and the Tel Aviv Stock Exchange (NYSE and TASE: ICL). The company employs more than 12,000 people worldwide, and its 2021 revenues totalled approximately $7 billion.
For more information, visit ICL’s website at www.icl-group.com.
To access ICL’s interactive ESG report, please click here.
PlantArcBio, Ltd. (PAB) is a public Ag-biotech company [TASE: PLNT], with an innovative and IP-protected Direct-In-Plant (DIP™) discovery platform, intended primarily for use in the agricultural industry, with a vision to contribute to the global food security and address sustainable agriculture. With its platform, the company discovers and develops novel genes and biological components that have beneficial effects on plants, such as yield improvement, drought resistance, and herbicide and insect tolerance. For more information, visit PlantArcBio’s website at www.plantarcbio.com.